Free Trial

Jazz Pharmaceuticals (JAZZ) Earnings Date, Estimates & Call Transcripts

$107.14
-1.25 (-1.15%)
(As of 09/6/2024 ET)
Skip Charts & View Estimated and Actual Earnings Data

JAZZ Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

JAZZ Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Jazz Pharmaceuticals Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany Guidance
Q1 20242$3.24$3.60$3.42 
Q2 20242$3.68$4.23$3.96 
Q3 20242$4.34$4.52$4.43 
Q4 20241$4.83$4.83$4.83 
FY 20247$16.09$17.18$16.64 
Q1 20251$3.13$3.13$3.13 
Q2 20251$4.08$4.08$4.08 
Q3 20251$4.34$4.34$4.34 
Q4 20251$4.53$4.53$4.53 
FY 20254$16.08$16.08$16.08 
Q1 20261$3.75$3.75$3.75 
Q2 20261$4.30$4.30$4.30 

JAZZ Earnings Date and Information

Jazz Pharmaceuticals has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, November 13th, 2024 based off prior year's report dates.

Jazz Pharmaceuticals Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks
11/13/2024
(Estimated)
------- 
5/1/2024Q1 2024$3.53$1.98($1.55)$4.19$938.99 million$901.98 million    
2/28/2024Q4 2023$4.44$4.40($0.04)$7.38$1.01 billion$1.01 billion        
11/8/2023Q3 2023$4.21$4.22+$0.01$6.30$969.47 million$972.14 million    
8/9/2023Q2 2023$3.68$3.83+$0.15$6.14$952.44 million$957.32 million    
5/10/2023Q1 2023$3.58$3.20($0.38)$5.36$898.11 million$892.81 million    
3/1/2023Q4 2022-($0.84)($0.84)$2.14$972.70 million$972.12 million    
11/9/2022Q3 2022$4.35$4.53+$0.18$9.37$939.88 million$940.65 million    
8/3/2022Q2 2022$3.63$3.62($0.01)$6.69$908.23 million$932.88 million    
5/4/2022Q1 2022$3.00$3.13+$0.13$6.23$853.73 million$813.72 million      
3/1/2022Q4 2021$2.98$3.66+$0.68$7.89$866.71 million$896.73 million  
11/9/2021Q3 2021$2.60$4.20+$1.60$8.14$829.98 million$838.12 million    
8/3/2021Q2 2021$3.08$3.90+$0.82$12.69$743.19 million$751.81 million    
5/4/2021Q1 2021$3.09$3.92+$0.83$4.75$613.07 million$607.58 million  
2/23/2021Q4 2020$3.58$4.00+$0.42$4.79$639.83 million$665.52 million    
11/2/2020Q3 2020$4.08$4.31+$0.23$5.08$577.62 million$600.90 million    
8/4/2020Q2 2020$3.11$3.71+$0.60$4.46$503.19 million$562.44 million    
5/5/2020Q1 2020$0.21$0.45+$0.24$2.72$544.55 million$534.73 million  
2/25/2020Q4 2019$3.61$4.42+$0.81$6.79$545.12 million$581.70 million    
11/5/2019Q3$3.19$4.10+$0.91$5.52$523.92 million$537.70 million    

Jazz Pharmaceuticals Earnings - Frequently Asked Questions

When is Jazz Pharmaceuticals's earnings date?

Jazz Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, November 13th, 2024 based off last year's report dates. Learn more on JAZZ's earnings history.

What guidance has Jazz Pharmaceuticals issued on next quarter's earnings?

Jazz Pharmaceuticals issued an update on its FY 2024 earnings guidance on Wednesday, July, 31st. The company provided earnings per share (EPS) guidance of 19.200-20.300 for the period, compared to the consensus estimate of 18.510. The company issued revenue guidance of $4.0 billion-$4.1 billion, compared to the consensus revenue estimate of $4.1 billion.

How much revenue does Jazz Pharmaceuticals generate each year?

Jazz Pharmaceuticals (NASDAQ:JAZZ) has a recorded annual revenue of $3.91 billion.

How much profit does Jazz Pharmaceuticals generate each year?

Jazz Pharmaceuticals (NASDAQ:JAZZ) has a recorded net income of $414.83 million. JAZZ has generated $4.85 earnings per share over the last four quarters.

What is Jazz Pharmaceuticals's price-to-earnings ratio?

Jazz Pharmaceuticals (NASDAQ:JAZZ) has a trailing price-to-earnings ratio of 22.09 and a forward price-to-earnings ratio of 6.68. The price/earnings-to-growth ratio is 1.45.

What is Jazz Pharmaceuticals's EPS forecast for next year?

Jazz Pharmaceuticals's earnings are expected to grow from $16.03 per share to $18.56 per share in the next year, which is a 15.78% increase.


More Earnings Resources from MarketBeat

This page (NASDAQ:JAZZ) was last updated on 9/7/2024 by MarketBeat.com Staff

From Our Partners